Drug shortages expose weaknesses in pharmaceutical manufacturing, supplier networks, and procurement. Discover the causes and how to improve supply resilience.
Drug shortages remain a persistent threat to pharmaceutical supply chains, even in well-resourced healthcare markets. The underlying causes often have little to do with the final delivery of medicines.
Instead, manufacturing failures, fragile supplier networks, poor commercial incentives, and weaknesses in procurement can disrupt availability long before a shortage reaches hospitals or pharmacies.
Image
The Growing Problem Behind Medicine Availability
Drug shortages affect the supply of essential medicines across therapeutic areas, but some products face considerably greater risks than others.
Generic medicines, antibiotics, anaesthetics, oncology treatments, and sterile injectable products feature prominently in shortage reports.
To manage and prevent drug shortages, we have to identify the most common causes.
In fact, many shortages originate in the early stages of pharmaceutical production and supply, while any response often begins only when medicines become difficult to obtain.
Research identifies several interconnected causes, including manufacturing problems, market pressures, fluctuating demand, supply-chain weaknesses, political decisions, and external disruptions.
Understanding these factors is important because a shortage rarely has just one cause. A manufacturing problem, for example, can become a much larger supply crisis when only a small number of companies produce the affected medicine.
Manufacturing Failures Put Essential Medicines At Risk
These problems can occur at several points in production, including raw material sourcing, processing, quality control, and final batch release.
Raw materials and active pharmaceutical ingredients
Pharmaceutical manufacturing depends on reliable access to active pharmaceutical ingredients (APIs), excipients, and packaging materials.
Shortages, contamination, inconsistent quality, or delays affecting these inputs can interrupt production.
Dependence on overseas suppliers adds another layer of exposure. If manufacturers rely on a limited number of sources for critical ingredients, disruptions in one location can affect production across several markets.
The problem goes beyond the API itself. A shortage of a specialised packaging component or another essential production material can also prevent a finished medicine from reaching the market.
Quality failures and production capacity
Manufacturing delays can also arise from:
Good Manufacturing Practice (GMP) non-compliance, which can lead to production interruptions and regulatory action.
Contamination and quality defects that require investigations, corrective measures, or product recalls.
Delays in testing and batch release, which hold finished products back from distribution.
Ageing equipment, limited manufacturing capacity, and complex production processes.
Sterile injectables are particularly vulnerable. Their production requires specialised facilities, controlled environments, and rigorous contamination prevention. Manufacturers cannot always transfer production quickly to another site when problems arise.
This helps explain why injectable antibiotics, anaesthetics, and oncology medicines repeatedly feature in shortage discussions.
How AI Is Opening New Opportunities in Fertility Care for Pharma
"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.
Image
Low Prices And Market Concentration Create Fragile Supply Chains
Not every shortage begins with a technical failure. The economics of pharmaceutical manufacturing can make continued production commercially unattractive.
Generic medicines often operate within highly competitive markets. Manufacturers face pressure to reduce prices, while production, quality assurance, regulatory compliance, and facility maintenance remain expensive.
When margins become too narrow, companies may reduce investment, withdraw products, or discontinue manufacturing altogether.
This can leave fewer suppliers responsible for meeting national or international demand.
The vulnerability becomes particularly serious when a medicine has only one manufacturer or when several nominal suppliers depend on the same production site or raw material source.
A U.S. government analysis of drug shortages found that sterile injectables accounted for 60% of brand-name shortages and 45% of generic shortages between 2018 and 2023. The analysis also highlighted the vulnerability of generic medicines to low profitability and concentrated manufacturing.
These figures illustrate why the number of registered suppliers does not necessarily reflect genuine supply-chain resilience. A market with several suppliers can still have a single point of failure.
Image
Demand, Distribution, and Procurement Add Further Supply Chain Pressures
Manufacturing capacity does not operate independently of market demand. Sudden increases in medicine consumption can overwhelm production systems that already operate with limited spare capacity.
Disease outbreaks, changes in clinical guidelines, seasonal demand, and the introduction of preferred treatments can all create unexpected pressure.
There are also several weaknesses in distribution and procurement:
Outdated purchasing policies: Procurement decisions based on historical consumption may fail to reflect changing clinical needs.
Just-in-time inventory practices: Limited stock across manufacturers, wholesalers, and healthcare providers leaves little protection against unexpected disruption.
Distribution delays: Transportation problems, storage failures, and poor stock management can interrupt deliveries.
Market allocation: Manufacturers may prioritise certain countries or customers when available supplies cannot meet total demand.
Limited supply transparency: Healthcare providers may receive insufficient information about the underlying causes or expected duration of shortages.
These factors can compound one another. A manufacturer facing reduced output may allocate available stock to selected markets, leaving other regions with limited supply.
Procurement policies that prioritise the lowest purchase price can also reinforce this problem if they overlook supplier reliability, manufacturing location, and continuity of supply.
Image
External Disruptions and Political Decisions Increase Exposure
Pharmaceutical supply chains also face risks beyond the direct control of manufacturers.
Natural disasters, geopolitical instability, cyberattacks, and changes in government policy can disrupt manufacturing, transportation, and access to critical materials.
Regulatory requirements and procurement processes can create additional pressure when they introduce delays or fail to provide sufficient incentives for reliable supply.
There is also a significant information problem in that the reasons behind many shortages remain unclear.
Manufacturers do not always disclose detailed explanations, making it difficult for healthcare providers and procurement teams to understand the underlying risk.
Without reliable information, organisations cannot easily distinguish between a temporary production delay, a quality problem, a commercial withdrawal, or a more persistent supply failure.
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Image
Why Must Pharmaceutical Supply Resilience Start Early?
There is an important weakness in conventional shortage management. Many interventions focus on finding alternative medicines, redistributing available stock, adjusting prescriptions, or sourcing products from other suppliers.
These measures are necessary, but they generally address the consequences rather than the original causes.
Pharmaceutical manufacturers and procurement leaders need greater visibility into supplier dependencies, production capacity, raw material availability, and the commercial sustainability of essential medicines.
This also means looking beyond the immediate supplier. A manufacturer may have several approved suppliers but still depend on the same upstream API producer, specialist component, or geographical manufacturing hub.
The U.S. Government Accountability Office has also highlighted the need for stronger coordination across government activities addressing drug shortages.
The strategic priority is that supply resilience must be created as part of manufacturing and procurement decisions before a shortage develops.
At Pharmatica, we examine the operational systems, manufacturing decisions, and supply-chain dependencies that shape medicine availability. Understanding where medicines shortages begin is essential to building more reliable Pharmaceutical Production and protecting access to essential treatments.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What are the main causes of pharmaceutical drug shortages?
The main causes include manufacturing failures, raw material shortages, quality problems, limited production capacity, low profit margins, supplier concentration, fluctuating demand, and distribution disruptions.
Why are generic medicines more vulnerable to shortages?
Generic medicines often operate with narrow profit margins. Manufacturers may reduce investment, discontinue products, or leave markets when production becomes commercially unattractive. This can reduce competition and concentrate supply among fewer companies.
Why are sterile injectable medicines frequently affected by shortages?
Sterile injectables require specialised manufacturing facilities, strict contamination controls, and complex quality processes. These requirements make production difficult to transfer between facilities when manufacturing problems occur.
How do supply-chain weaknesses contribute to drug shortages?
Dependence on limited API suppliers, overseas manufacturing, inadequate inventory, distribution delays, and poor supply transparency can interrupt the movement of medicines from production facilities to healthcare providers.
How can pharmaceutical manufacturers prevent drug shortages?
Manufacturers can strengthen supply resilience through supplier diversification, better production planning, investment in manufacturing quality, improved inventory management, and early identification of supply-chain risks.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
3
Why not support
Nicole Dale
by giving this content a like
An Overview of EuroQol EQ-5D: Quality-of-Life Assessment
EuroQol EQ-5D explained: How it measures quality of life, supports QALYs and HTA decisions, and what new EuroQol tools mean for clinical trial strategy.
We explain why paediatric clinical trials remain underfunded, and how better study design, global collaboration, and new technologies can improve medicines for children.
Comments (0)